AMRN
Price
$16.00
Change
+$0.55 (+3.56%)
Updated
Sep 26 closing price
Capitalization
330.92M
BIIB
Price
$137.37
Change
+$1.70 (+1.25%)
Updated
Sep 26 closing price
Capitalization
20.14B
24 days until earnings call
Interact to see
Advertisement

AMRN vs BIIB

Header iconAMRN vs BIIB Comparison
Open Charts AMRN vs BIIBBanner chart's image
Amarin
Price$16.00
Change+$0.55 (+3.56%)
Volume$69.55K
Capitalization330.92M
Biogen
Price$137.37
Change+$1.70 (+1.25%)
Volume$1.68M
Capitalization20.14B
AMRN vs BIIB Comparison Chart in %
Loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRN vs. BIIB commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Buy and BIIB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (AMRN: $16.00 vs. BIIB: $137.37)
Brand notoriety: AMRN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMRN: 114% vs. BIIB: 107%
Market capitalization -- AMRN: $330.92M vs. BIIB: $20.14B
AMRN [@Pharmaceuticals: Major] is valued at $330.92M. BIIB’s [@Pharmaceuticals: Major] market capitalization is $20.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $649.52B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, AMRN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s).

  • AMRN’s TA Score: 4 bullish, 5 bearish.
  • BIIB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than AMRN.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а +4.23% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -3.60% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.20%. For the same industry, the average monthly price growth was -0.44%, and the average quarterly price growth was +12.50%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.20% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($20.1B) has a higher market cap than AMRN($331M). AMRN YTD gains are higher at: 64.948 vs. BIIB (-10.169). BIIB has higher annual earnings (EBITDA): 2.79B vs. AMRN (-70.12M). BIIB has more cash in the bank: 2.76B vs. AMRN (299M). AMRN has less debt than BIIB: AMRN (7.34M) vs BIIB (6.6B). BIIB has higher revenues than AMRN: BIIB (10B) vs AMRN (219M).
AMRNBIIBAMRN / BIIB
Capitalization331M20.1B2%
EBITDA-70.12M2.79B-3%
Gain YTD64.948-10.169-639%
P/E RatioN/A13.15-
Revenue219M10B2%
Total Cash299M2.76B11%
Total Debt7.34M6.6B0%
FUNDAMENTALS RATINGS
AMRN vs BIIB: Fundamental Ratings
AMRN
BIIB
OUTLOOK RATING
1..100
1770
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9674
PRICE GROWTH RATING
1..100
4259
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMRN's Valuation (90) in the Pharmaceuticals Other industry is in the same range as BIIB (91) in the Biotechnology industry. This means that AMRN’s stock grew similarly to BIIB’s over the last 12 months.

AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as BIIB (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (74) in the Biotechnology industry is in the same range as AMRN (96) in the Pharmaceuticals Other industry. This means that BIIB’s stock grew similarly to AMRN’s over the last 12 months.

AMRN's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as BIIB (59) in the Biotechnology industry. This means that AMRN’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (92) in the Biotechnology industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that BIIB’s stock grew similarly to AMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRNBIIB
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
53%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
57%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 12 days ago
55%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 4 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
63%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
AMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INGVF26.030.44
+1.73%
ING Groep N.V.
JUSHF0.61N/A
+0.05%
Jushi Holdings Inc.
IMIAF29.50N/A
N/A
IMI plc
LMPMY3.63N/A
N/A
Lee & Man Paper Manufacturing Ltd.
ADXRF0.02N/A
N/A
ADX Energy Ltd.

AMRN and

Correlation & Price change

A.I.dvisor tells us that AMRN and OGN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMRN and OGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRN
1D Price
Change %
AMRN100%
+3.56%
OGN - AMRN
28%
Poorly correlated
+0.89%
PFE - AMRN
25%
Poorly correlated
+0.68%
SNY - AMRN
23%
Poorly correlated
+1.04%
BIIB - AMRN
22%
Poorly correlated
+1.25%
NVO - AMRN
22%
Poorly correlated
-0.77%
More

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.25%
PFE - BIIB
55%
Loosely correlated
+0.68%
MRK - BIIB
51%
Loosely correlated
+1.24%
AMGN - BIIB
49%
Loosely correlated
+0.66%
GSK - BIIB
46%
Loosely correlated
+0.84%
NVS - BIIB
46%
Loosely correlated
+1.16%
More